The CooperCOO +4.04%85 Days Payable is 60.52 as of Apr. 2026, which is 5% below its 10-year median of 63.88. GuruFocus rates COO with a GF Score™ of 85/100 and a GF Value™ of $100.87 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 795 Medical Devices & Instruments companies, The Cooper ranks worse than 55.22% on this metric.
The Cooper's average Accounts Payable for the
three
months ended in Apr. 2026 was $230 Mil. The Cooper's Cost of Goods Sold for the
three
months ended in Apr. 2026 was $346 Mil.
Hence, The Cooper's Days Payable for the
three
months ended in Apr. 2026 was 60.52.
The historical rank and industry rank for The Cooper's Days Payable or its related term are showing as below:
COO'
s Days Payable Range Over the Past 10 Years
Min: 51.58 Med: 63.88 Max: 75.45
Current: 63.08
During the past 13 years, The Cooper's highest Days Payable was 75.45. The lowest was 51.58. And the median was 63.88.
COO's Days Payable is ranked worse than 55.22% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs COO: 63.08
The Cooper's Days Payable
declined
from Apr. 2025 (62.92) to Apr. 2026 (60.52).
It may suggest that The Cooperaccelerated paying its suppliers.
The Cooper Days Payable Related Terms
The Cooper Days Payable Historical Data
* Premium members only.
The historical data trend for The Cooper's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, The Cooper's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Days Payable distribution charts can be found below:
* The bar in red indicates where The Cooper's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
The Cooper's Days Payable for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper (COO) has a Days Payable of 60.52 as of Apr. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on The Cooper and its competitors. This is near median its historical median of 63.88. Over the past decade, The Cooper's Days Payable has ranged from 51.58 to 75.45. According to the industry distribution chart, The Cooper ranks #439 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 55.2%.
Is The Cooper's Days Payable too high?
The Cooper's current Days Payable of 60.52 is near median its 10-year median of 63.88. Over the past 10 years, this metric has ranged from a low of 51.58 to a high of 75.45. The Medical Devices & Instruments industry median Days Payable is 67.87. The Cooper's value of 60.52 is 10.8% below this industry median. Based on the distribution chart, The Cooper ranks #439 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, The Cooper has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's Days Payable compare to ALGN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #439 out of 795 companies for Days Payable. This places The Cooper in the lower half of its industry. The industry median Days Payable is 67.87. The Cooper's value of 60.52 is 10.8% below this benchmark. Historically, The Cooper's own Days Payable has ranged from 51.58 to 75.45 over the past decade. While the company's 10-year median is 63.88 vs. the industry median of 67.87, The Cooper has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current Days Payable of 60.52 is 10.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current Days Payable is 60.52, which is near median its own 10-year median of 63.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Significantly Undervalued. The stock's GF Value™ is $100.87, compared to a current price of $68.86 — trading 31.7% below its estimated fair value. The current Days Payable is 60.52, which is near median its 10-year median of 63.88 and 10.8% below the Medical Devices & Instruments industry median of 67.87. The Cooper's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For The Cooper (COO), the current Days Payable is 60.52 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $68.86 is trading 31.7% below its estimated GF Value™ of $100.87.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for COO:
Days Payable: 60.52 (near median its 10-year median of 63.88)
GF Value™: $100.87 vs. price of $68.86 (31.7% below fair value)
Industry Position: 10.8% below the Medical Devices & Instruments median (#439 of 795)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
85GF Score
Get the complete analysis for COO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
